Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tacrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 16/20 | 1.00 |
| ▸ | BCHE known ✓ | P06276 | 14/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.97 |
| ▸ | GRIN2A | Q12879 | 8/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.97 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.97 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.97 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.97 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.97 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tacrine SCHEMBL2330283 | 1.00 | ACHE (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL2330285 | 1.00 | ACHE (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL490750 | 1.00 | ACHE (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL3270 | 1.00 | ACHE (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL7638777 | 1.00 | ACHE (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL2236694 | 0.98 | THRB (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL5580054 | 0.98 | THRB (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL29681895 | 0.98 | ACHE (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL29594645 | 0.98 | ACHE (1.00) | ACHEBCHETSHRHSD17B10THRB | |
| Tacrine SCHEMBL2828 | 0.98 | ACHE (1.00) | ACHEBCHETSHRHSD17B10THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4222144-B1 | SUCCINATE SALTS OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[D]IMIDAZOL-2-AMINE, PREPARATION THEREOF AND USE OF THE SAME | ALZPROTECT (FR) | 2026-05-20 | — | — | EP | disclosed |
| CN-122036622-A | Succinate salt of N- (3- (4- (3- (diisobutylamino) propyl) piperazin-1-yl) propyl) -1H-benzo [ d ] imidazol-2-amine, preparation and use thereof | 雅尔兹普罗泰特公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4429648-B1 | NOVEL SYNERGISTIC COMBINATIONS BASED ON FLUOROETHYLNOREMMANTINE (FENM) AND AN ACETYLCHOLINESTERASE INHIBITOR FOR USE IN THE TREATMENT OF NEURODEGEATIVE DISEASES | REST THERAPEUTICS (FR) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025217267-A1 | PLATFORM FOR BIO-BASED PRODUCTION OF HIGH LEVELS OF O-PHOSPHOSERINE, CYSTEATE OR TAURINE | NATÁUR INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4532469-A1 | SPLEEN TYROSINE KINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20250000818-A1 | NEW SYNERGISTIC COMBINATIONS BASED ON FENM AND AN ACETYLCHOLINESTERASE INHIBITOR | REST THERAPEUTICS (FR) | 2025-01-02 | — | — | US | disclosed |
| WO-2024206168-A9 | BIOPRODUCTION OF SULFUR-CONTAINING COMPOUNDS | NATÁUR LLC (US) | 2024-10-31 | — | — | WO | disclosed |
| EP-4440735-A1 | A MICROCAPSULE AND METHODS OF MAKING AND USING SAME | Vilnius University (LT) | 2024-10-09 | — | — | EP | disclosed |
| WO-2024206168-A1 | BIOPRODUCTION OF SULFUR-CONTAINING COMPOUNDS | NATÁUR LLC (US) | 2024-10-03 | — | — | WO | disclosed |
| EP-4429648-A1 | NEW SYNERGISTIC COMBINATIONS BASED ON FENM AND AN ACETYLCHOLINESTERASE INHIBITOR | REST THERAPEUTICS (FR) | 2024-09-18 | — | — | EP | disclosed |
| US-20080108574-A1 | MELANOCORTIN RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080103105-A1 | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103165-A1 | PPAR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008039863-A2 | COMPOSITION COMPRISING A MELANOCORTIN RECEPTOR (MCR) MODULATING AGENT ALONE OR IN COMBINATION WITH A SECOND NEUROGENIC AGENT FOR TREATING NERVOUS SYSTEM DISORDERS | BRAINCELLS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008036678-A2 | COMBINATION COMPRISING A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGENT AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER, INCREASING NEURODIFFERENTIATION AND INCREASING NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036846-A2 | COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITOR AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER AND INCREASING NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008030651-A1 | COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE | BRAINCELLS, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20080064671-A1 | COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE | BRAINCELLS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108574-A1 | MELANOCORTIN RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | MC1R, MC3R, MC5R | ACHE 403/4885BCHE 961/4885TSHR 387/4885 |
| US-20080103105-A1 | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS | HMGCR, DCX, SREBF1 | ACHE 986/4885BCHE 489/4885TSHR 2711/4885 |
| US-20080103165-A1 | PPAR MEDIATED MODULATION OF NEUROGENESIS | PPARG, PPARA, PPARD | ACHE 978/4885BCHE 1442/4885TSHR 499/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | ACHE 18/4885BCHE 42/4885TSHR 302/4885 |
| US-20080064671-A1 | COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE | GRIN2C, COQ8A, GRIN2D | ACHE 25/4885BCHE 664/4885TSHR 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.